New combo aims to shrink big lung tumors for better radiation results
NCT ID NCT04765709
First seen Jan 04, 2026 · Last updated Apr 28, 2026 · Updated 17 times
Summary
This study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy could shrink large stage III lung cancers enough to allow safe radiation therapy. About 10 people took part. The goal was to see if more patients could become eligible for radiation compared to historical results. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER (STAGE III) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Gustave Roussy Institute
Paris, France
-
Vall d'Hebron Barcelona Hospital
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.